Cargando…

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

BACKGROUND: CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively. Their role in cancer immunotherapy needs to be elucidated. METHODS: Patients with advanced non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dal Bello, M. G., Filiberti, R. A., Alama, A., Orengo, A. M., Mussap, M., Coco, S., Vanni, I., Boccardo, S., Rijavec, E., Genova, C., Biello, F., Barletta, G., Rossi, G., Tagliamento, M., Maggioni, C., Grossi, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408784/ https://www.ncbi.nlm.nih.gov/pubmed/30849967 http://dx.doi.org/10.1186/s12967-019-1828-0

Ejemplares similares

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019)

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Zhou, Wenwen, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)

Retracted: Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Healthcare Engineering, Journal of
Publicado: (2023)

Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
por: Vanni, Irene, et al.
Publicado: (2015)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
por: Coco, Simona, et al.
Publicado: (2017)

Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction
por: Yuan, Jingmin, et al.
Publicado: (2022)

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
por: Carbone, Federico, et al.
Publicado: (2021)

Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer
por: Zhang, Yunxia, et al.
Publicado: (2020)

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer
por: Coco, Simona, et al.
Publicado: (2019)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018)

Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring
por: He, Xiang, et al.
Publicado: (2022)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma
por: Truini, Anna, et al.
Publicado: (2017)

The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer
por: Xu, Liu, et al.
Publicado: (2016)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Cusato, Jessica, et al.
Publicado: (2019)

Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma
por: Ju, Mengyang, et al.
Publicado: (2022)

Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis
por: Boher, J-M, et al.
Publicado: (1999)

Triplexed CEA-NSE-PSA Immunoassay Using Time-Gated Terbium-to-Quantum Dot FRET
por: Bhuckory, Shashi, et al.
Publicado: (2020)

Diagnostic value of CT and MRI combined with serum LDH, NSE, CEA, and MYCN in pediatric neuroblastoma
por: Hao, Jumei, et al.
Publicado: (2023)

Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015)

Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
por: He, Ying, et al.
Publicado: (2017)

Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
por: Shang, Liqun, et al.
Publicado: (2021)

Simple diagnosis of cancer by detecting CEA and CYFRA 21-1 in saliva using electronic sensors
por: Joshi, Sowmya, et al.
Publicado: (2022)

Retracted: Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples
por: Bonfiglio, Silvia, et al.
Publicado: (2016)

Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Alama, Angela, et al.
Publicado: (2017)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples
por: Thomas, D S, et al.
Publicado: (2015)

The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
por: Zhao, Tongwei, et al.
Publicado: (2021)

The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer
por: Li, Jiezhou, et al.
Publicado: (2021)

Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2022)

血清TPS、CEA、Pro-GRP和CYFRA21-1水平在肺癌患者中的临床意义
Publicado: (2010)

Retracted: The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
por: Rijavec, Erika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fq3419mmecvgp69u0em2j8qi6m